E-LIB Suche - Ergebnisse für: Banerjee, Subhashis

1

P096 Deucravacitinib, an oral, selective, allosteric tyrosi..:

Kearney, Niamh ; Pink, Andrew ; Hoyt, Kim...
British Journal of Dermatology. 191 (2024) Supplement_1 - p. i60-i61 , 2024

Link: https://doi.org/10.1093/..

2

Biochemical, Biomarker, and Behavioral Characterization of ..:

Smith, Denise M. ; Aggarwal, Geetika ; Niehoff, Michael L....
Molecular Neurobiology. , 2024

Link: https://doi.org/10.1007/..

3

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Ki..:

Alexis, Andrew F. ; Merola, Joseph F. ; Zhong, Yichen...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s358 , 2024

Link: https://doi.org/10.25251..

4

Deucravacitinib in Plaque Psoriasis: 3-year Safety and Effi..:

Armstrong, April W. ; Lebwohl, Mark ; Warren, Richard B....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s366 , 2024

Link: https://doi.org/10.25251..

5

Deucravacitinib Long-Term Efficacy in Week 16 Placebo Cross..:

Lebwohl, Mark ; Warren, Richard B. ; Imafuku, Shinichi...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s365 , 2024

Link: https://doi.org/10.25251..

6

Plain Language Summary of the PAISLEY study: deucravacitini..:

Morand, Eric F. ; Pike, Marilyn ; Merrill, J...
Expert Opinion on Investigational Drugs. 33 (2024) 5 - p. 431-440 , 2024

Link: https://doi.org/10.1080/..

7

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Poo..:

Strober, Bruce ; Blauvelt, Andrew ; Warren, Richard B....
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

8

Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inh..:

Gottlieb, Alice B. ; Armstrong, April W. ; Merola, Joseph F....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s383 , 2024

Link: https://doi.org/10.25251..

9

Streamlining neuroradiology workflow with AI for improved c..:

Banerjee, Subhashis ; Nysjö, Fredrik ; Toumpanakis, Dimitrios...
Scientific Reports. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

10

Deucravacitinib in plaque psoriasis: 2-year safety and effi..:

Lebwohl, Mark ; Warren, Richard B ; Sofen, Howard...
British Journal of Dermatology. 190 (2024) 5 - p. 668-679 , 2024

Link: https://doi.org/10.1093/..

11

Traceable mixnets:

Agrawal, Prashant ; Nakarmi, Abhinav ; Jhanwar, Mahabir Prasad..
Proceedings on Privacy Enhancing Technologies. 2024 (2024) 2 - p. 235-275 , 2024

Link: https://doi.org/10.56553..

12

Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in t..:

Blauvelt, Andrew ; Korman, Neil J. ; Merola, Joseph F....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s364 , 2024

Link: https://doi.org/10.25251..

13

Deucravacitinib onset of action and maintenance of response..:

Korman, Neil J. ; Warren, Richard B. ; Bagel, Jerry...
Journal of Dermatological Treatment. 35 (2024) 1 - p. , 2024

Link: https://doi.org/10.1080/..

14

Deucravacitinib, an oral, selective, allosteric tyrosine ki..:

Imafuku, Shinichi ; Okubo, Yukari ; Tada, Yayoi...
The Journal of Dermatology. 51 (2024) 3 - p. 365-379 , 2024

Link: https://doi.org/10.1111/..

15

Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Bi..:

FitzGerald, Oliver ; Gladman, Dafna D. ; Mease, Philip J....
Arthritis & Rheumatology. , 2024

Link: https://doi.org/10.1002/..